1. Home
  2. NAC vs MLYS Comparison

NAC vs MLYS Comparison

Compare NAC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California Quality Municipal Income Fund

NAC

Nuveen California Quality Municipal Income Fund

SELL

Current Price

$10.16

Market Cap

1.8B

Sector

Finance

ML Signal

SELL

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$20.29

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAC
MLYS
Founded
1998
2019
Country
France
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
1998
2023

Fundamental Metrics

Financial Performance
Metric
NAC
MLYS
Price
$10.16
$20.29
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $46.33
AVG Volume (30 Days)
★ 1.6M
1.4M
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 4.33%
N/A
EPS Growth
N/A
★ 37.43
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.80
$20.41
52 Week High
$12.25
$47.65

Technical Indicators

Market Signals
Indicator
NAC
MLYS
Relative Strength Index (RSI) 41.72 32.24
Support Level $9.80 N/A
Resistance Level $12.04 $31.19
Average True Range (ATR) 0.17 1.27
MACD 0.04 -0.29
Stochastic Oscillator 66.38 4.06

Price Performance

Historical Comparison
NAC
MLYS

About NAC Nuveen California Quality Municipal Income Fund

Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: